Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics
NVCT Price/Volume Stats
| Current price | $6.72 | 52-week high | $18.65 |
| Prev. close | $6.72 | 52-week low | $6.20 |
| Day low | $6.44 | Volume | 40,165 |
| Day high | $6.83 | Avg. volume | 99,450 |
| 50-day MA | $8.41 | Dividend yield | N/A |
| 200-day MA | $10.36 | Market Cap | 119.41M |
NVCT Stock Price Chart Interactive Chart >
Nuvectis Pharma Inc. (NVCT) Company Bio
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Latest NVCT News From Around the Web
Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in CholangiocarcinomaMitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 American Association for Cancer Research ("AACR"))NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023 Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pha |
Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their HoldingsQuite a few insiders have dramatically grown their holdings in Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) over the past 12... |
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business HighlightsPhase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800 Granted Orphan Drug Designation for the Treatment of CholangiocarcinomaNXP800 Phase 1a and Preclinical Data Presentations for NXP800 and NXP900 at Key Medical Conferences FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a cli |
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial CancerFort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA). Abstract Titles and PresentersPresentation Detai |
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
NVCT Price Returns
| 1-mo | -23.20% |
| 3-mo | -17.95% |
| 6-mo | -26.88% |
| 1-year | -51.48% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -19.42% |
| 2023 | 11.20% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...